One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk’s outlook is brightening. Most Read from Fast Company None of the objects on top of the Oval Office mantle were made in the U.S. ACM Awards 2025: How to watch the Academy of Country Music Awards live online or on a smart TV for free Why the guards who protect the conclave are wearing those crazy uniforms Novo Nordisk, the Danish company that produces the semaglutide drugs Ozempic and Wegovy, saw its shares rise more than 7% Wednesday, in spite of recent headwinds from widely available copycat versions of its signature weight-loss drugs. Following its quarterly earnings report, shares of the company rose to $71.53 before leveling off and settling around $67.70, in spite of lowered expectations for the year. Novo Nordisk lowered its sales growth forecast for 2025, now expecting growth between 13% and 21%, down from the 16% to 24% it projected back in February. The company blamed the dip on slower-than-expected uptake of its branded glucagon-like peptide-1 (GLP-1) drugs, largely due to competition from compounding pharmacies, which had been filling the gap as demand for weight-loss meds like Wegovy outpaced supply. FDA crackdown signals end of GLP-1 copycats But that pressure is expected to ease. The Food and Drug Administration recently declared the shortage over and has officially banned large-scale compounding of GLP-1 drugs like semaglutide. With those off-brand versions now illegal in the U.S., Novo Nordisk and its investors are optimistic sales will rebound in the coming months. The agency has given large compounding pharmacies in the U.S. until May 22 to wind down production of those drugs or face potential enforcement actions. Late last month, a U.S. judge rejected a legal challenge from an industry group representing compounding pharmacies that could have allowed continued production of GLP-1 copycat drugs to continue. While their products can be cheaper for consumers, drugs produced in compounding pharmacies face less regulatory scrutiny than their name-brand counterparts. The FDA acknowledges that while compounded drugs are a lawful option that alleviates supply problems, they may not meet the same quality and safety standards. WeightWatchers collapses under pressure The future is decidedly less sunny for longtime weight-loss industry stalwart WeightWatchers, which announced that it would pursue Chapter 11 bankruptcy protection on Tuesday. The company has struggled to reinvent itself in the era of widely available weight-loss drugs, even as it embraced their rise by pivoting to sell compounded semaglutide through its own online pharmacy. Story Continues WeightWatchers may be down, but the company insists that it isn’t out. WeightWatchers insists that it will continue to operate normally in spite of its bankruptcy plans, which it described as “transformational” in a press release. “There will be no impact to members or the plans they rely on to support their weight management goals,” the company said. After the process is complete, a new investor group will wield 91% of the company and the remaining chunk of stock will be held by existing shareholders. “The decisive actions we’re taking today, with the overwhelming support of our lenders and noteholders, will give us the flexibility to accelerate innovation, reinvest in our members, and lead with authority in a rapidly evolving weight management landscape,” WeightWatchers CEO Tara Comonte said. “As the conversation around weight shifts toward long-term health, our commitment to delivering the most trusted, science-backed, and holistic solutions—grounded in community support and lasting results—has never been stronger, or more important,” she added. A new generation of GLP-1 drugs promising fast results continues to rock the weight-loss industry, which has emphasized dieting and other slow behavioral changes for decades. Whether WeightWatchers can weather the storm remains to be seen, but complete transformation might be the only option if the 60-year-old company plans to make it in the Wegovy era. This post originally appeared at fastcompany.com Subscribe to get the Fast Company newsletter: http://fastcompany.com/newsletters View Comments
Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...